Tags

Type your tag names separated by a space and hit enter

5,7-dihydroxytryptamine injections into the prefrontal cortex and nucleus accumbens differently affect prepulse inhibition and baseline startle magnitude in rats.
Behav Brain Res. 2009 Aug 24; 202(1):58-63.BB

Abstract

The prefrontal cortex and the nucleus accumbens are two brain sites which are known to be involved in the modulation of the acoustic startle response. In particular, the release of monoaminergic transmitters within these brain sites plays an important role in prepulse inhibition of the startle response which serves as an operational measure of sensorimotor gating. Like for dopamine, it is well established that serotonin transmission plays an important role in prepulse inhibition. However, there are only few studies investigating the effects of local manipulation of serotonin transmission on prepulse inhibition. The aim of the present study was to test whether prepulse inhibition or the startle response itself was affected by serotonergic depletion of either the prefrontal cortex or the nucleus accumbens. Serotonergic depletion was induced by local injections of 5,7-dihydroxytryptamine and verified by ex vivo analysis of transmitter levels by high pressure liquid chromatography. In our behavioural tests, we found that 5,7-dihydroxytryptamine into the prefrontal cortex decreased prepulse inhibition, whereas injections into the nucleus accumbens facilitated prepulse inhibition. The time course of these behavioural effects, as well as the transmitter level changes within the different brain sites was very different. Most interestingly, 5,7-dihydroxytryptamine injections into the nucleus accumbens affect serotonin and dopamine levels in both, nucleus accumbens and prefrontal cortex. Taken together, the present study supports an important role of serotonin in the modulation of prepulse inhibition and baseline startle magnitude. However, the observed changes cannot be attributed to a specific brain site since our data clearly show that local 5,7-dihydroxytryptamine injections also affect transmitter levels in brain sites away from the injection site.

Authors+Show Affiliations

Animal Physiology, University of Tübingen, Tübingen, Germany.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19447281

Citation

Mohr, Daniela, et al. "5,7-dihydroxytryptamine Injections Into the Prefrontal Cortex and Nucleus Accumbens Differently Affect Prepulse Inhibition and Baseline Startle Magnitude in Rats." Behavioural Brain Research, vol. 202, no. 1, 2009, pp. 58-63.
Mohr D, von Ameln-Mayerhofer A, Fendt M. 5,7-dihydroxytryptamine injections into the prefrontal cortex and nucleus accumbens differently affect prepulse inhibition and baseline startle magnitude in rats. Behav Brain Res. 2009;202(1):58-63.
Mohr, D., von Ameln-Mayerhofer, A., & Fendt, M. (2009). 5,7-dihydroxytryptamine injections into the prefrontal cortex and nucleus accumbens differently affect prepulse inhibition and baseline startle magnitude in rats. Behavioural Brain Research, 202(1), 58-63. https://doi.org/10.1016/j.bbr.2009.03.014
Mohr D, von Ameln-Mayerhofer A, Fendt M. 5,7-dihydroxytryptamine Injections Into the Prefrontal Cortex and Nucleus Accumbens Differently Affect Prepulse Inhibition and Baseline Startle Magnitude in Rats. Behav Brain Res. 2009 Aug 24;202(1):58-63. PubMed PMID: 19447281.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 5,7-dihydroxytryptamine injections into the prefrontal cortex and nucleus accumbens differently affect prepulse inhibition and baseline startle magnitude in rats. AU - Mohr,Daniela, AU - von Ameln-Mayerhofer,Andreas, AU - Fendt,Markus, Y1 - 2009/03/21/ PY - 2008/11/20/received PY - 2009/03/06/revised PY - 2009/03/11/accepted PY - 2009/5/19/entrez PY - 2009/5/19/pubmed PY - 2009/8/20/medline SP - 58 EP - 63 JF - Behavioural brain research JO - Behav. Brain Res. VL - 202 IS - 1 N2 - The prefrontal cortex and the nucleus accumbens are two brain sites which are known to be involved in the modulation of the acoustic startle response. In particular, the release of monoaminergic transmitters within these brain sites plays an important role in prepulse inhibition of the startle response which serves as an operational measure of sensorimotor gating. Like for dopamine, it is well established that serotonin transmission plays an important role in prepulse inhibition. However, there are only few studies investigating the effects of local manipulation of serotonin transmission on prepulse inhibition. The aim of the present study was to test whether prepulse inhibition or the startle response itself was affected by serotonergic depletion of either the prefrontal cortex or the nucleus accumbens. Serotonergic depletion was induced by local injections of 5,7-dihydroxytryptamine and verified by ex vivo analysis of transmitter levels by high pressure liquid chromatography. In our behavioural tests, we found that 5,7-dihydroxytryptamine into the prefrontal cortex decreased prepulse inhibition, whereas injections into the nucleus accumbens facilitated prepulse inhibition. The time course of these behavioural effects, as well as the transmitter level changes within the different brain sites was very different. Most interestingly, 5,7-dihydroxytryptamine injections into the nucleus accumbens affect serotonin and dopamine levels in both, nucleus accumbens and prefrontal cortex. Taken together, the present study supports an important role of serotonin in the modulation of prepulse inhibition and baseline startle magnitude. However, the observed changes cannot be attributed to a specific brain site since our data clearly show that local 5,7-dihydroxytryptamine injections also affect transmitter levels in brain sites away from the injection site. SN - 1872-7549 UR - https://www.unboundmedicine.com/medline/citation/19447281/57_dihydroxytryptamine_injections_into_the_prefrontal_cortex_and_nucleus_accumbens_differently_affect_prepulse_inhibition_and_baseline_startle_magnitude_in_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166-4328(09)00161-2 DB - PRIME DP - Unbound Medicine ER -